Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.

Pulley JM, Rhoads JP, Jerome RN, Challa AP, Erreger KB, Joly MM, Lavieri RR, Perry KE, Zaleski NM, Shirey-Rice JK, Aronoff DM.

Annu Rev Pharmacol Toxicol. 2019 Jul 23. doi: 10.1146/annurev-pharmtox-010919-023537. [Epub ahead of print]

PMID:
31337270
2.

A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection.

Choby JE, Monteith AJ, Himmel LE, Margaritis P, Shirey-Rice JK, Pruijssers A, Jerome RN, Pulley J, Skaar EP.

Infect Immun. 2019 Apr 23;87(5). pii: e00031-19. doi: 10.1128/IAI.00031-19. Print 2019 Mar.

PMID:
30782860
3.

Reply to Ward and Colleagues' Comment on "Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors".

Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, Bernard G, Ekstrom L, Lancaster WJ, Denny JC.

Drug Saf. 2018 Nov;41(11):1101. doi: 10.1007/s40264-018-0701-z. No abstract available.

PMID:
30066313
4.

Advocating for mutually beneficial access to shelved compounds.

Pulley JM, Jerome RN, Shirey-Rice JK, Zaleski NM, Naylor HM, Pruijssers AJ, Jackson JC, Bernard GR, Holroyd KJ.

Future Med Chem. 2018 Jun 1;10(12):1395-1398. doi: 10.4155/fmc-2018-0090. Epub 2018 May 23. No abstract available.

PMID:
29788759
5.

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS.

Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Review.

6.

When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

Pulley JM, Jerome RN, Zaleski NM, Shirey-Rice JK, Pruijssers AJ, Lavieri RR, Chettiar SN, Naylor HM, Aronoff DM, Edwards DA, Niswender CM, Dugan LL, Crofford LJ, Bernard GR, Holroyd KJ.

Assay Drug Dev Technol. 2017 Dec;15(8):354-361. doi: 10.1089/adt.2017.821. Epub 2017 Dec 1.

7.

Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.

Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, R Bernard G, B Ekstrom L, Lancaster WJ, Denny JC.

Drug Saf. 2018 Mar;41(3):303-311. doi: 10.1007/s40264-017-0616-0.

8.

Mining 100 million notes to find homelessness and adverse childhood experiences: 2 case studies of rare and severe social determinants of health in electronic health records.

Bejan CA, Angiolillo J, Conway D, Nash R, Shirey-Rice JK, Lipworth L, Cronin RM, Pulley J, Kripalani S, Barkin S, Johnson KB, Denny JC.

J Am Med Inform Assoc. 2018 Jan 1;25(1):61-71. doi: 10.1093/jamia/ocx059.

9.

Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.

Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, Bastarache L, Niu X, Holroyd KJ, Roden DM, Skaar EP, Niswender CM, Marnett LJ, Lindsley CW, Ekstrom LB, Bentley AR, Bernard GR, Hong CC, Denny JC.

Assay Drug Dev Technol. 2017 Apr;15(3):113-119. doi: 10.1089/adt.2016.772. Epub 2017 Apr 5.

10.

Norepinephrine transporter heterozygous knockout mice exhibit altered transport and behavior.

Fentress HM, Klar R, Krueger JJ, Sabb T, Redmon SN, Wallace NM, Shirey-Rice JK, Hahn MK.

Genes Brain Behav. 2013 Nov;12(8):749-59. doi: 10.1111/gbb.12084. Epub 2013 Oct 9.

11.

Norepinephrine transporter variant A457P knock-in mice display key features of human postural orthostatic tachycardia syndrome.

Shirey-Rice JK, Klar R, Fentress HM, Redmon SN, Sabb TR, Krueger JJ, Wallace NM, Appalsamy M, Finney C, Lonce S, Diedrich A, Hahn MK.

Dis Model Mech. 2013 Jul;6(4):1001-11. doi: 10.1242/dmm.012203. Epub 2013 Apr 4.

Supplemental Content

Loading ...
Support Center